PD-1/PD-L1 inhibitory peptide C8

PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model[1].

Product Specifications

UNSPSC

12352209

Target

PD-1/PD-L1

Related Pathways

Immunology/Inflammation

Field of Research

Cancer

Smiles

O=C(N[C@@H](CCCCN)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CCCNC(N)=N)C(N4[C@@H](CCC4)C(N[C@@H](CO)C(N[C@H]5CCC(O)=O)=O)=O)=O)=O)=O)=O)[C@H](CSSC[C@@H](C(O)=O)NC5=O)N

Molecular Formula

C51H72N14O14S2

Molecular Weight

1169.33

References & Citations

[1]Zhai W, et al., Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy. Sci China Life Sci. 2021 Apr;64 (4) :548-562.